Degludec Audit ABCD Manchester, Spring 2016 - Poster

Degludec improves minor, severe & nocturnal hypoglycaemia in Type 1 diabetes: Association of British Clinical Diabetologists (ABCD) nationwide degludec audit

A Lumb1, R Abraham2, R Harper3, SC Bain4, R Rea1, REJ Ryder5 on behalf of the ABCD nationwide degludec audit contributors

1Oxford University Hospitals NHS Foundation Trust, Oxford

2London Medical Clinic, London

3The Ulster Hospital, Belfast

4Abertawe Bro Morgannwg University NHS Trust, Swansea/Neath

5Sandwell and West Birmingham Hospitals NHS Trust, Birmingham

Discipline

Diabetes
Resource taxonomy
Audit Posters
Clinical taxonomy
Treatments for diabetes Type 2 diabetes mellitus
Listing status
Archived

ABCD Corporate Pharma Sponsors

Gold

  • AstraZeneca UK
  • Boehringer Ingelheim and Lilly Alliance
  • Eli Lilly and Company

Silver

  • A Menarini Farmaceutica Internazionale SRL
  • Sanofi

ABCD Corporate Pump & Device Sponsors

Gold

  • Abbott
  • Dexcom
  • Ypsomed Ltd

Silver

  • A. Menarini Diagnostics
  • Advanced Therapeutics (UK) Ltd
  • Air Liquide Healthcare Ltd
  • Insulet International
  • Medtronic Limited

Bronze

  • Roche Diabetes Care

Contact

Address for correspondence: 
ABCD (Diabetes Care) Ltd, 483 Green Lanes, London, N13 4BS

Telephone: 01675 477602
Email: info@abcd.care

Follow Us

ABCD (Diabetes Care) is a company limited by shares in England and Wales under company number 7270377, whose registered address is Fifteen Rosehill, Montgomery Way, Rosehill Estate, Carlisle CA1 2RW Diabetes Care Trust (ABCD) is a registered charity number 1139057, a company limited by guarantee in England and Wales under company number 74248361, whose registered address is Fifteen Rosehill, Montgomery Way, Rosehill Estate, Carlisle CA1 2RW. ABCD (Diabetes Care) Ltd is a wholly owned subsidiary of the Diabetes Care Trust (ABCD) Ltd